Top in cardiology: Colchicine and COVID-19, CAC scoring, heart disease statistics
Click Here to Manage Email Alerts
Colchicine was associated with a 20% reduction in hospitalization and mortality among patients with COVID-19, according to topline results of the COLCORONA randomized trial. It was the top story in cardiology last week.
Other top stories include an editorial about the National Lipid Association’s scientific statement on coronary artery calcium scoring for primary coronary atherosclerosis prevention and an update from the American Heart Association on heart disease and stroke statistics.
Read these and more top stories in cardiology below:
COLCORONA topline results: Colchicine reduces hospitalization, death in COVID-19
According to a press release from the Montreal Heart Institute, the COLCORONA trial indicates colchicine, an anti-inflammatory drug primarily used to treat gout, could prevent cytokine storm and other complications in patients with COVID-19 compared with placebo. Read more.
NLA scientific statement further cements CAC scoring in primary prevention
The first technique for coronary artery calcium scoring was published in 1990. Given the lack of data at the time on CAC and coronary atherosclerosis burden, the algorithm was remarkable yet unactionable. Read more.
AHA: Heart disease remains leading cause of death worldwide; trends discouraging
Heart disease remains the leading cause of death globally, according to the annual heart disease and strokes statistics update from the American Heart Association. Read more.
In acute ischemic stroke, women present with greater severity than men
Women admitted for acute ischemic stroke more often presented with a higher degree of disability and were more likely to undergo intra-arterial thrombolysis compared with men, according to research published in Stroke. Read more.
Radiofrequency ablation system for paroxysmal AF gains FDA approval
Medtronic announced the FDA approved its temperature-controlled, irrigated radiofrequency ablation system with diamonds for the treatment of paroxysmal atrial fibrillation that is unresponsive to drug therapy. Read more.